ArticleDrug target insights2017

Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is Overkill.

Jagannadha AvasaralaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.